A biotechnology drug developer focused on treatments for cancer, immune disorders, and inflammatory diseases. Its portfolio historically included blockbuster therapies such as Revlimid and Pomalyst for blood cancers, making the company a major player in oncology drug markets. Investors closely follo...
5 members of Congress have disclosed 28 trades in Celgene Corporation (CELG), a Healthcare company. The buy/sell breakdown shows 21 purchases versus 6 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2010-05-02 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-01-12 | JAMES B. RENACCI | buy | $1,294.17 |
| 2010-01-02 | JAMES B. RENACCI | sell | $2,328.00 |
| 2009-09-12 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2009-06-04 | JANE HARMAN | sell | $1K – $15K |
| 2009-06-01 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2009-04-01 | JOE SESTAK | exchange | Below $1,000 |
| 2009-01-06 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2008-11-04 | MICHAEL T. MCCAUL | buy | — |
| 2008-11-04 | MICHAEL T. MCCAUL | buy | — |
| 2008-08-09 | MICHAEL T. MCCAUL | buy | — |
| 2008-08-09 | MICHAEL T. MCCAUL | buy | — |
| 2008-08-01 | Lamar Smith | buy | $3,758.58 |
| 2008-05-09 | MICHAEL T. MCCAUL | buy | — |
| 2008-05-09 | MICHAEL T. MCCAUL | sell | — |
| 2008-03-09 | MICHAEL T. MCCAUL | buy | — |
| 2008-03-09 | MICHAEL T. MCCAUL | buy | — |
| 2008-01-08 | MICHAEL T. MCCAUL | buy | — |
| 2008-01-08 | MICHAEL T. MCCAUL | buy | — |
| 2008-01-08 | MICHAEL T. MCCAUL | sell | — |
| 2008-01-08 | MICHAEL T. MCCAUL | buy | — |
| 2007-07-08 | Lamar Smith | sell | $853.47 |
| 2007-06-11 | JANE HARMAN | buy | $50K – $100K |
| 2006-01-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2005-02-08 | Lamar Smith | buy | $2,123.73 |
| 2001-08-08 | Lamar Smith | buy | $2,442.18 |
| 2001-08-08 | Lamar Smith | buy | $6,759.00 |
| 2001-06-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |